SCHEMBL847115

SCHEMBL847115

COCc1cc(NC(C)=O)ccc1C=CS(=O)(=O)N1CCC2(CC1)N=C(C1CCC(C)CC1)NC2=O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTH1R Q03431 6/20 0.52
▸ KDM4E B2RXH2 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ CALCRL Q16602 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 5/20 0.33
▸ LMNA P02545 1/20 0.32
▸ ATAD2 Q6PL18 2/20 0.31
▸ CECR2 Q9BXF3 2/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ ENPP2 Q13822 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL847114 1.00 PTH1R (0.52) PTH1RKDM4EHSD17B10NPC1RAB9A
SCHEMBL849269 0.93 PTH1R (0.51) PTH1RKDM4EHSD17B10NPC1RAB9A
SCHEMBL849268 0.93 PTH1R (0.51) PTH1RKDM4EHSD17B10NPC1RAB9A
SCHEMBL847619 0.93 PTH1R (0.55) PTH1RKDM4EHSD17B10NPC1RAB9A
SCHEMBL847620 0.93 PTH1R (0.55) PTH1RKDM4EHSD17B10NPC1RAB9A
SCHEMBL849618 0.89 PTH1R (0.51) PTH1RKDM4EHSD17B10NPC1RAB9A
SCHEMBL849617 0.89 PTH1R (0.51) PTH1RKDM4EHSD17B10NPC1RAB9A
SCHEMBL849030 0.87 PTH1R (0.51) PTH1RKDM4EHSD17B10CALCRLALDH1A1
SCHEMBL849029 0.87 PTH1R (0.51) PTH1RKDM4EHSD17B10CALCRLALDH1A1
SCHEMBL849971 0.85 PTH1R (0.49) PTH1RKDM4EHSD17B10NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 — — EP claimed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 — — EP claimed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US claimed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 — — EP claimed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 — — US disclosed
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-21 — — US disclosed
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 — — EP disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 — — US disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 — — EP disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 PTH1R 1869/4885KDM4E 2949/4885HSD17B10 2057/4885
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 PTH1R 1869/4885KDM4E 2949/4885HSD17B10 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback